Projektbeschreibung
Europäisch-lateinamerikanisches Netzwerk zur Frühdiagnose von Leberkrebs
Tumore der Leber, der Gallengänge und der Gallenblase sind weltweit eine häufige Todesursache. In Lateinamerika treten sie jedoch besonders aggressiv in Erscheinung. Die überdurchschnittliche Mortalität bei diesen Tumoren liegt vor allem daran, dass zuverlässige Untersuchungsmethoden fehlen, aber auch an der Komplexität der Diagnosestellung, für die hochmoderne Bildgebungstechnologie und Proben aus schlecht erreichbaren Geweben notwendig sind. Im EU-finanzierten Projekt ESCALON kommt nun ein Team aus europäischen und lateinamerikanischen Fachleuten aus klinischer Praxis und Grundlagenforschung zusammen, die Expertise aus Immunologie und Proteomik mitbringen. Das Team will neue Instrumente finden, um frühe Entstehungsphasen von Leberkrebs vorhersagen zu können. Diese sollen leicht verfügbar sein und so die durch Krebs verursachte Sterblichkeit dramatisch reduzieren.
Ziel
Hepatobiliary malignancies represent a major cause of mortality globally and are uniquely aggressive in Latin America. The most common tumors are: hepatocellular carcinoma (HCC) affecting young individuals in Latin America and being the second most common cause of cancer-related death worldwide; cholangiocarcinoma (CCA) with minimal survival upon diagnosis and largely understudied in the region; gallbladder cancer (GBC) being a rare tumor worldwide but representing the second most common cause of cancer-related death in women in Chile. Key factors related to the excessive mortality of these tumors are the lack of reliable screening methods and the complexity of diagnosis, which requires advanced imaging technology and difficult-to-access tissue. These barriers are amplified by poor accessibility present in resource-limited regions, all of which leads to tumors being diagnosed at advanced stages in which curative therapy is not an option.
To overcome these barriers, we propose to: A) validate immune-related markers in serum to predict HCC in South America and evaluate factors associated to early HCC development; B) define the utility of extracellular vesicles in serum as biomarkers for diagnosis of CCA and determine genetic and infectious factors that increase risk for this cancer; and C) identify biomarkers for GBC detection and evaluate novel immune factors that affect the geographical impact of this tumor.
This project advances the field by focusing on a unique approach to screen and diagnose tumors based on serum detection of biomarkers before a tumor is visible on imaging, allowing for early tumor detection in a cost effective manner that will lead to implementation of curative therapies. In addition, this project addresses modifiable risk factors for hepatobiliary tumors that could be targeted for prevention. This project will result in novel tools that are easily accessible and will dramatically reduce the burden of cancer-related mortality in Latin America.
Wissenschaftliches Gebiet
Schlüsselbegriffe
Programm/Programme
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenUnterauftrag
H2020-SC1-2018-Single-Stage-RTD
Finanzierungsplan
RIA - Research and Innovation actionKoordinator
3015 GD Rotterdam
Niederlande